FDA warned Thrasio/ZymaDerm that its ZymaDerm for Molluscum is an unapproved new drug marketed without FDA approval.
What happened
FDA reviewed the company's website and Facebook page on May 11, 2023, and observed that ZymaDerm for Molluscum was offered for sale in the U.S. with claims to treat molluscum contagiosum. FDA said the product is a drug intended to treat disease but is not generally recognized as safe and effective and has no approved new drug application. FDA also said the claims are especially concerning because the product is marketed for use in children and may delay proper diagnosis or treatment.
What FDA found
Website claims show the product is intended to treat molluscum contagiosum, making it a drug.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The product is a new drug because it is not generally recognized as safe and effective for its claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)There is no FDA-approved application for the product, so selling or shipping it violates the approval requirement.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)FDA says the homeopathic label does not exempt the product, and its 'other ingredients' count as active under FDA labeling rules because the website promotes them with disease claims.
FD&C Act section 201(g)(1); 21 C.F.R. 201.66(b)(2)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with supporting documents. If the company disagrees or cannot complete corrections in that time, FDA asks for its reasoning and a completion timeline.
Who should pay attention
- retailers and marketplaces selling ZymaDerm or similar molluscum products
- parents and caregivers of children with skin lesions
- companies marketing homeopathic or 'natural' drugs with disease-treatment claims
This is a summary. Read the original letter on fda.gov.